Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Forbes JF, et al. Lancet. 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11. Lancet. 2016. PMID: 26686313 Free PMC article. Clinical Trial.
Breast cancer management pathways during the COVID-19 pandemic: outcomes from the UK 'Alert Level 4' phase of the B-MaP-C study.
Dave RV, Kim B, Courtney A, O'Connell R, Rattay T, Taxiarchi VP, Kirkham JJ, Camacho EM, Fairbrother P, Sharma N, Cartlidge CWJ, Horgan K, McIntosh SA, Leff DR, Vidya R, Potter S, Holcombe C, Copson E, Coles CE, Cutress RI, Gandhi A, Kirwan CC; B-MaP-C study collaborative. Dave RV, et al. Br J Cancer. 2021 May;124(11):1785-1794. doi: 10.1038/s41416-020-01234-4. Epub 2021 Mar 25. Br J Cancer. 2021. PMID: 33767422 Free PMC article.
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders C, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A; IBIS-II investigators. Cuzick J, et al. Lancet. 2014 Mar 22;383(9922):1041-8. doi: 10.1016/S0140-6736(13)62292-8. Epub 2013 Dec 12. Lancet. 2014. PMID: 24333009 Free article. Clinical Trial.
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study.
Dave RV, Elsberger B, Taxiarchi VP, Gandhi A, Kirwan CC, Kim B, Camacho EM, Coles CE, Copson E, Courtney A, Horgan K, Fairbrother P, Holcombe C, Kirkham JJ, Leff DR, McIntosh SA, O'Connell R, Pardo R, Potter S, Rattay T, Sharma N, Vidya R, Cutress RI; B-MaP-C study collaborative. Dave RV, et al. Breast Cancer Res Treat. 2023 Jun;199(2):265-279. doi: 10.1007/s10549-023-06893-4. Epub 2023 Apr 3. Breast Cancer Res Treat. 2023. PMID: 37010651 Free PMC article.
144 results